Validating protein biomarkers november
The m RNA levels of ITGA4, LCN2, CPNE3 and SERPINB1 were found to be altered significantly in the WBCs of breast cancer patients.
The levels of SERPINB1 (Serpin B1, neutrophil elastase inhibitor) and CPNE3 (Copine 3, phospholipid binding protein) were assessed using Western blotting.
These analyses demonstrated the association of SERPINB1 with breast cancer metastases, and suggested its potential utility as a biomarker of poor prognosis and treatment efficacy.
Classification of p SS requires four of six criteria, including a positive minor salivary gland biopsy or antibody to SS-A/SS-B.
Blood tests can determine if a patient has high levels of anti-Ro/SSA and anti-La/SSB.
The disease may occur alone as primary SS (p SS) or present as secondary SS (s SS), when it is associated with other autoimmune diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).
Further quantitative validation of SERPINB1 in a larger panel of WBCs by ELISA will be required for a clinical phase in the biomarker development pipeline.No conclusive results were obtained for CPNE3 and, together with ITGA4, LCN2 and other additional candidate biomarkers (to be selected from the initial list), they will be tested further.
We also develop innovative tests associated with the identified biomarker so that you can benefit from a reliable test which is validated with clinicians.The combination of protein biomarkers B2M and two m RNA biomarkers, MNDA and GIP2, reached an ROC of 0.95 in discriminating p SS from SLE.We have successfully verified a panel of protein and m RNA biomarkers that can discriminate p SS from both SLE and healthy controls.Rituximab is a chimeric monoclonal antibody against the B-cell surface antigen CD20.Initial clinical trials suggested that rituximab is an effective agent in the treatment of SS and associated MALT lymphoma (4-10).The shortlisted 15 genes were then validated using Real-Time Quantitative Reverse Transcription PCR (RT-q PCR).